Evidence map›Paper›PMID 41282905›Full record

ArticlemedRxiv : the preprint server for health sciences2025

A digital twin methodology using real patient data for sample size reduction in Alzheimer's disease randomized controlled clinical trials.

Daniel Andrews, Shirin Golchi, D Louis Collins

Abstract readPreprint
In one paragraph

Article in medRxiv : the preprint server for health sciences, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

3 authors.

Daniel AndrewsDepartment of Biomedical Engineering, McGill University, Montreal, Canada.ORCID 0000-0003-3610-4664
Shirin GolchiDepartment of Epidemiology, Biostatistics and Occupational Health, McGill University.ORCID 0000-0003-3382-9563
D Louis CollinsDepartment of Biomedical Engineering, McGill University, Montreal, Canada.ORCID 0000-0002-8432-7021

Funding

Project 1U19AG024904 · NIA · NORTHERN CALIFORNIA INSTITUTE/RES/EDU · PI MONICA G. RIVERA-MINDT · 2016 to 2026
$226.7M
NIA NIH HHS U19 AG024904
6 · The paper itself

Abstract

introductionRecruitment for Alzheimer's disease randomized controlled trials (RCTs) is difficult and expensive. To reduce RCT sample sizes, our Digital Twin Trial (DTT) methodology combines an interpretable cognitive decline prediction model with prediction-powered inference.

methodsFor DTT participants, our model identifies similar individuals ("Digital Twins") from a retrospective database and uses their cognitive scores to predict decline. Predictions adjust observed scores, reducing variance within treatment groups. We simulated 18-month DTTs and standard RCTs using mixed effects models of decline in Alzheimer's Disease Neuroimaging Initiative subjects meeting lecanemab's Phase 3 inclusion criteria.

resultsPredicted and observed change in Clinical Dementia Rating Sum-of-Boxes correlated at DISCUSSION: DTTs could reduce recruitment and cost burdens. Model interpretability could help clinicians trust individualized prognoses.

Indexed as

Alzheimer’s diseaseclinical trialcognitive declinedata analysisdementiadigital twinsdrug treatmentlecanemablongitudinal datamild cognitive impairmentPhase 3predictionsimulationstatistical powerType 1 error

Identifiers

PMID41282905
PMCPMC12636686

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.